| Code | CSB-RA847747MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to the reference antibody LB-LR-1109, targeting LILRB1 (Leukocyte Immunoglobulin-Like Receptor B1), also known as ILT2, CD85j, or MIR-7. LILRB1 is an inhibitory receptor expressed primarily on myeloid cells and B lymphocytes that plays a critical role in immune regulation by recognizing classical and non-classical MHC class I molecules. Upon ligand binding, LILRB1 delivers inhibitory signals through its immunoreceptor tyrosine-based inhibitory motifs (ITIMs), suppressing immune cell activation and inflammatory responses. This immunomodulatory function has significant implications in cancer immunology, where LILRB1 contributes to tumor immune evasion, as well as in autoimmune disorders and transplantation tolerance.
This biosimilar antibody replicates the binding characteristics and specificity of LB-LR-1109, providing researchers with a reliable tool for investigating LILRB1-mediated immune suppression mechanisms. It is particularly valuable for studies exploring checkpoint inhibition strategies, myeloid cell function, tumor microenvironment interactions, and immune tolerance pathways. The antibody supports diverse research applications aimed at understanding LILRB1's role in disease pathogenesis and therapeutic intervention.
There are currently no reviews for this product.